JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB214468

Anti-NCR1/NKp46 antibody

4

(4 Reviews)

|

(17 Publications)

Rabbit Polyclonal NCR1 antibody. Suitable for WB and reacts with Mouse, Human samples. Cited in 17 publications. Immunogen corresponding to Synthetic Peptide within Human NCR1 aa 150-250 conjugated to Keyhole Limpet Haemocyanin.

View Alternative Names

CD335, LY94, NCR1, Natural cytotoxicity triggering receptor 1, Lymphocyte antigen 94 homolog, NK cell-activating receptor, Natural killer cell p46-related protein, NK-p46, NKp46, hNKp46

2 Images
Western blot - Anti-NCR1/NKp46 antibody (AB214468)
  • WB

Lab

Western blot - Anti-NCR1/NKp46 antibody (AB214468)

Upper band could be the result of glycosylation

All lanes:

Western blot - Anti-NCR1/NKp46 antibody (ab214468) at 1/300 dilution

All lanes:

Raji cell lysates

Secondary

All lanes:

conjugated secondary antibody at 1/20000 dilution

Predicted band size: 34 kDa

false

Western blot - Anti-NCR1/NKp46 antibody (AB214468)
  • WB

Supplier Data

Western blot - Anti-NCR1/NKp46 antibody (AB214468)

All lanes:

Western blot - Anti-NCR1/NKp46 antibody (ab214468) at 1/1000 dilution

Lane 1:

Mouse lymph node lysate

Lane 2:

Mouse spleen lysate

Secondary

All lanes:

Conjugated secondary antibody at 1/20000 dilution

Predicted band size: 34 kDa

false

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

No

Reacts with

Mouse, Human

Applications

WB

applications

Immunogen

Synthetic Peptide within Human NCR1 aa 150-250 conjugated to Keyhole Limpet Haemocyanin. The exact immunogen used to generate this antibody is proprietary information.

O76036

style
left-column

Alternative Products

Primary Antibodies

AB224703

Anti-NCR1/NKp46 antibody [EPR22403-57]

RabMAb|Recombinant|20ul selling size

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-NCR1/NKp46 antibody [EPR22403-57] (AB224703)

  • 0
  • 0
Primary Antibodies

AB14823

Anti-NCR1/NKp46 antibody [n1D9]

Flow Cytometry - Anti-NCR1/NKp46 antibody [n1D9] (AB14823)

  • 0
  • 0
Primary Antibodies

AB233808

Anti-NCR1/NKp46 antibody [2B11E12]

Flow Cytometry - Anti-NCR1/NKp46 antibody [2B11E12] (AB233808)

  • 0
  • 0
Primary Antibodies

AB199128

Anti-NCR1/NKp46 antibody

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-NCR1/NKp46 antibody (AB199128)

  • 0
  • 0
Primary Antibodies

AB89877

Anti-NCR1/NKp46 antibody [MM0491-8F24]

  • 5
  • 4

Complementary Products

Primary Antibodies

AB16669

Anti-CD3 epsilon antibody [SP7]

BOND RX™ Validated|RabMAb|Advanced Validation|Recombinant|Lab Essentials|20ul selling size

Multiplex immunohistochemistry - Anti-CD3 epsilon antibody [SP7] (AB16669)

  • 4
  • 79
Primary Antibodies

AB217344

Anti-CD8 alpha antibody [EPR21769]

RabMAb|Recombinant

Flow Cytometry - Anti-CD8 alpha antibody [EPR21769] (AB217344)

  • 5
  • 6
Primary Antibodies

AB183685

Anti-CD4 antibody [EPR19514]

RabMAb|Recombinant|Lab Essentials|20ul selling size

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CD4 antibody [EPR19514] (AB183685)

  • 5
  • 21
Primary Antibodies

AB20034

Anti-FOXP3 antibody [236A/E7]

BOND RX™ Validated|Recombinant|Lab Essentials|Advanced Validation

Multiplex immunohistochemistry - Anti-FOXP3 antibody [236A/E7] (AB20034)

  • 4
  • 38
style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/300", "WB-species-notes": "<p></p>" }, "Mouse": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/300", "WB-species-notes": "<p></p>" }, "Rat": { "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "" } } }
style
left-column
style
left-column

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.4 Preservative: 0.02% Proclin 300 Constituents: 50% Glycerol (glycerin, glycerine), 48.98% TBS, 1X, 1% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

NCR1 also known as NKp46 is a receptor mainly expressed on the surface of natural killer (NK) cells. Its primary role involves recognizing and binding to ligands present on target cells including tumor cells and virus-infected cells. NCR1 initiates the activation of NK cells leading to the destruction of these abnormal cells. The NCR1 protein has a molecular weight of approximately 46 kDa and is a part of the immunoglobulin superfamily. NCR1 is mainly expressed in the immune system specifically on NK cells which are an important component of the innate immune response.
Biological function summary

The function of NCR1 involves the recognition of stressed transformed or infected cells marking them for elimination by NK cells. It does not typically function as a part of a complex; rather it serves a somewhat autonomous role in cell signaling. However its interaction with other receptors on NK cells including DAP12 enhances its signaling capabilities. Through the activation of cascades NCR1 promotes the release of cytotoxic granules and the production of cytokines therefore mediating the immune response.

Pathways

NCR1 plays a significant role in the regulation of immune surveillance pathways. It is involved in the recognition and elimination pathways that modulate the immune response against infected or cancerous cells. NK cells with NCR1's involvement interact with receptors like NKG2D adjusting the NK cell's cytotoxic activity. These interactions coordinate the broader immune response important for innate immunity effectively bridging innate and adaptive immunity by influencing other immune cells.

NCR1 has been implicated in cancer and infectious diseases. In cancer altered expression or dysfunction of NCR1 may contribute to the evasion of immune surveillance by tumor cells potentially leading to tumor progression. Studies have shown reduced NKp46 expression in some cancerous states linking it to poor prognosis. In infectious diseases NCR1 plays a role in targeting virus-infected cells and its dysfunction can result in reduced effectiveness in clearing viral infections. Interactions with viral envelope proteins can interfere with NCR1 activity exemplifying its importance in antiviral defense mechanisms.
style
left-column
style
left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

Target data

Cytotoxicity-activating receptor that may contribute to the increased efficiency of activated natural killer (NK) cells to mediate tumor cell lysis.
See full target information NCR1
style
left-column

Publications (17)

Recent publications for all applications. Explore the full list and refine your search

iScience 26:108341 PubMed38047079

2023

Host-microbiome interactions in distinct subsets of preterm labor and birth.

Applications

Unspecified application

Species

Unspecified reactive species

Jose Galaz,Roberto Romero,Jonathan M Greenberg,Kevin R Theis,Marcia Arenas-Hernandez,Yi Xu,Marcelo Farias-Jofre,Derek Miller,Tomi Kanninen,Valeria Garcia-Flores,Nardhy Gomez-Lopez

Journal of breast cancer 26:186-200 PubMed37051644

2023

Inhibition of Tumor Growth and Metastasis by Newcastle Disease Virus Strain P05 in a Breast Cancer Mouse Model.

Applications

Unspecified application

Species

Unspecified reactive species

Oscar Antonio Ortega-Rivera,Pamela Gallegos-Alcalá,Mariela Jiménez,J Luis Quintanar,Flor Torres-Juarez,Bruno Rivas-Santiago,Susana Del Toro-Arreola,Eva Salinas

Pharmaceutics 15: PubMed36839699

2023

An Engineered IFNγ-Antibody Fusion Protein with Improved Tumor-Homing Properties.

Applications

Unspecified application

Species

Unspecified reactive species

Cesare Di Nitto,Ettore Gilardoni,Jacqueline Mock,Lisa Nadal,Tobias Weiss,Michael Weller,Frauke Seehusen,Chiara Libbra,Emanuele Puca,Dario Neri,Roberto De Luca

Cancer research communications 2:725-738 PubMed35937458

2022

The Combination of Radiotherapy and Complement C3a Inhibition Potentiates Natural Killer cell Functions Against Pancreatic Cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Quaovi H Sodji,Dhanya K Nambiar,Vignesh Viswanathan,Rie von Eyben,Deana Colburg,Michael S Binkley,Caiyun G Li,Monica M Olcina,Daniel T Chang,Quynh-Thu Le,Amato J Giaccia

Clinical & translational immunology 11:e1364 PubMed35003748

2022

SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models.

Applications

Unspecified application

Species

Unspecified reactive species

Chun-Bong Synn,Sung Eun Kim,Hee Kyu Lee,Min-Hwan Kim,Jae Hwan Kim,Ji Min Lee,Ha Ni Jo,Wongeun Lee,Dong Kwon Kim,Youngseon Byeon,Young Seob Kim,Mi Ran Yun,Chae-Won Park,Jiyeon Yun,Sangbin Lim,Seong Gu Heo,San-Duk Yang,Eun Ji Lee,Seul Lee,Hunmi Choi,You Won Lee,Jae Seok Cho,Do Hee Kim,Sungho Park,Jung-Ho Kim,Yewon Choi,Sung Sook Lee,Beung-Chul Ahn,Chang Gon Kim,Sun Min Lim,Min Hee Hong,Hye Ryun Kim,Kyoung-Ho Pyo,Byoung Chul Cho

Neuroendocrinology 112:370-383 PubMed34157710

2021

Analysis of Immune Landscape in Pancreatic and Ileal Neuroendocrine Tumours Demonstrates an Immune Cold Tumour Microenvironment.

Applications

Unspecified application

Species

Unspecified reactive species

Lulu Tanno,Salma Naheed,Jonathan Dunbar,Jo Tod,Maria A Lopez,Julian Taylor,Maria Machado,Bryan Green,Margaret Ashton-Key,Serena J Chee,Oliver Wood,Neil W Pearce,Gareth J Thomas,Peter S Friedmann,Judith Cave,Christian H Ottensmeier

Scientific reports 11:12988 PubMed34155309

2021

SIRT2 promotes murine melanoma progression through natural killer cell inhibition.

Applications

Unspecified application

Species

Unspecified reactive species

Manchao Zhang,Scarlett Acklin,John Gillenwater,Wuying Du,Mousumi Patra,Hao Yu,Bo Xu,Jianhua Yu,Fen Xia

Cell stem cell 28:1597-1613.e7 PubMed33945793

2021

CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance.

Applications

Unspecified application

Species

Unspecified reactive species

Cheng Wang,Yang Li,Lingfei Jia,Jin Koo Kim,Jiong Li,Peng Deng,Wuchang Zhang,Paul H Krebsbach,Cun-Yu Wang

EBioMedicine 57:102850 PubMed32574962

2020

Immune-infiltration based signature as a novel prognostic biomarker in gastrointestinal stromal tumour.

Applications

Unspecified application

Species

Unspecified reactive species

Zhe-Wei Wei,Jing Wu,Wei-Bin Huang,Jin Li,Xiao-Fang Lu,Yu-Jie Yuan,Wen-Jun Xiong,Xin-Hua Zhang,Wei Wang,Yu-Long He,Chang-Hua Zhang

Frontiers in pharmacology 11:8 PubMed32116691

2020

A Novel C Type CpG Oligodeoxynucleotide Exhibits Immunostimulatory Activity and Enhances Antitumor Effect .

Applications

Unspecified application

Species

Unspecified reactive species

Tete Li,Jing Wu,Shan Zhu,Guoxia Zang,Shuang Li,Xinping Lv,Wenjun Yue,Yuan Qiao,Jiuwei Cui,Yan Shao,Jun Zhang,Yong-Jun Liu,Jingtao Chen
View all publications
style
left-column
style
left-column
style
right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com